Australia Markets closed

Biotron Limited (BIT.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
0.021-0.00 (-8.70%)
At close: 2:50PM AEST

Biotron Limited

56 Delhi Road
Suite 19
North Ryde, NSW 2113
61 2 9805 0488

Full-time employees4

Key executives

Dr. Michelle Miller BSc, MSc, Ph.D., GCertAppFin (Finsia)Chief Exec. Officer, Managing Director and Exec. DirectorN/AN/AN/A
Mr. Peter James Nightingale B.Econ, CACompany Sec.N/AN/A60
Dr. John Wilkinson Ph.D.Chief Scientific OfficerN/AN/AN/A
Amounts are as of 31December,2016, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.


Biotron Limited, a biotechnology company, develops and commercializes novel small molecule antiviral therapeutics targeting Hepatitis C virus (HCV) and HIV-1 in Australia. Its lead antiviral drug is BIT225, a viroporin inhibitor that has completed Phase II clinical trial for the treatment of HCV, HIV, and HIV/HCV infections. The company also has various earlier stage preclinical research programs for other viral infections, including dengue. Biotron Limited is based in North Ryde, Australia.

Corporate governance

Biotron Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.